



ASX Announcement

30 October 2018

Creso establishes Global Centre of Edible Cannabis Product Development and Research in Nova Scotia, Canada

Highlights:

- **Creso develops, manufactures and distributes hemp and cannabis based human and animal edible products in countries globally**
- **To meet the growing need for trusted hemp and cannabis edible products Creso is establishing a Centre of Excellence**
- **The Global Centre of Edible Cannabis Product Development and Research is located in the newly constructed Good Manufacturing Practice (“GMP”) quality facility in Nova Scotia, Canada**
- **The Centre will focus on innovative, pharma-quality products with optimized delivery technologies**
- **Creso has also established a relationship with key academic research institutions in Switzerland, Canada, Colombia and Israel**

Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to announce it has established the first dedicated Research and Development Center (the “Centre”) in the area of medical and nutritional edible cannabis in its Mernova Medicinal Site in Nova Scotia, Canada.

The Centre will focus on unique, edible formulations utilizing precision engineered cannabis extracts and non cannabis ingredients that, when combined, deliver an enhanced experience. This Centre will further establish Creso as the leader in producing trusted, pharma-grade, edible cannabis products.

Creso has relationships with academic institutions in each country where it has operations (Canada, Switzerland, Colombia and Israel) and will leverage this for additional support in research, analytical insights and product innovation.

“For the first time we see a company bringing together international knowledge in the field of medicinal and nutritional cannabis. It’s a fascinating initiative” said Prof. Dr. Felix Gutzwiller, former Director of the Institute for Prevention and Public Health at the University of Zürich.



“This is a great example of consolidated international academic research work being applied directly in practice.”

“Creso has the substantial competitive advantage of being operationally present in those countries which have the scientific and operational lead in medicinal cannabis namely Canada, Israel and Colombia,” said Boaz Wachtel, Chairman of Creso.

“This will lead to substantial patient benefits and improved health outcomes through more accurate therapeutic approaches with medicinal cannabis.”

Creso’s COO John Griese said: “Following successful launches of cannaQIX®10 and cannaQIX® 50 it is clear demand for safe, effective, edible products is growing at a tremendous rate. It is not only a good business decision but it’s our responsibility in this emerging industry to apply rigour to cannabis product design. The Centre will assume this responsibility on behalf of Creso.”

Creso’s Co-founder and CEO Dr. Miri Halperin Wernli, said: “In our development and research centre we will create high-quality, purposefully designed and lab-tested products which will cater for specific applications such as sleep, pain or anxiety. The products will be enriched with appealing terpene profiles enhancing their health and wellness benefits.

“Like with fine wine and craft beer, premium cannabis consumers want enhanced experiences that fit their lifestyle and from premium products of the highest quality. Creso is dedicated to taking an active role in setting the standards for the cannabis industry and performing beyond expectations to make safe, reliable products. The Centre of Edible Cannabis Product Development and Research is one big step toward that vision.”

Creso is also in advanced talks with the National University of Colombia in Bogota and University of Antioquia (UdeA), Medellin for local operational and research and development activities.

Substantial funds have been allocated to the installation of the GMP lab, test kitchen and processing capability. Building construction is complete and the facility is expected to be operational by end Q1 2019.

---ENDS---



About Creso Pharma Ltd (www.cresopharma.com)

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso, and their respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation. The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward looking statements speak only as of the date of this announcement Creso does not have any obligation to update such statements except to the extent required by applicable laws.

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney NSW 2000
E: info@everblucapital.com
P: +61 2 8249 000